Therefore, we propose a new mechanism of ADORA2A-mediated metabolic-epigenetic cascade via the ERK/MYC/PYCR/SIRT6/7 axis in promoting lineage plasticity and resistance to targeted therapy in cancer cells. This evidence concerns the gene ADORA2A and cancer.